Holen Sie sich die Stockscreener-App
0.2922
0.59%
0.0017
Schlusskurs vom Vortag:
$0.2905
Offen:
$0.2943
24-Stunden-Volumen:
109.40K
Relative Volume:
0.15
Marktkapitalisierung:
$27.74M
Einnahmen:
$1.22M
Nettoeinkommen (Verlust:
$-14.15M
KGV:
-1.1238
EPS:
-0.26
Netto-Cashflow:
$-6.55M
1W Leistung:
+4.32%
1M Leistung:
-2.57%
6M Leistung:
-20.21%
1J Leistung:
-10.64%
1-Tages-Spanne:
$0.2914
$0.2954
1-Wochen-Bereich:
$0.28
$0.31
52-Wochen-Spanne:
$0.2525
$0.4985
IGC Pharma Inc Stock (IGC) Company Profile
Firmenname
IGC Pharma Inc
Sektor
Branche
Telefon
301-983-0998
Adresse
4336 Montgomery Avenue, Bethesda, MD
Vergleichen Sie IGC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IGC
IGC Pharma Inc
|
0.2919 | 27.61M | 1.22M | -14.15M | -6.55M | -0.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.54 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.61 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.92 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
357.53 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
335.75 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
IGC Pharma Inc Aktie (IGC) Neueste Nachrichten
Aug Volume: Should I buy SONY stock nowEarnings Growth Summary & Verified Momentum Stock Ideas - baoquankhu1.vn
IGC Pharma announces registered direct equity offering financing - MSN
IGC Pharma Expands Phase 2 CALMA Trial With New Clinical Trial Site at Integrative Clinical Trials in New York - 富途资讯
IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York - Finviz
IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial S - GuruFocus
IGC Expands Alzheimer's Clinical Trial with New Site in Brooklyn - GuruFocus
NYC clinic joins trial of cannabinoid drug for Alzheimer's agitation - Stock Titan
Retail Trends: Whats the MACD signal for Invesco QQQ Trust Series 12025 Market Outlook & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Performance Recap: Is IGC Pharma Inc a cyclical or defensive stockJuly 2025 Update & Real-Time Market Trend Scan - baoquankhu1.vn
Does IGC Pharma Inc stock have upside surprise potentialMarket Risk Summary & Technical Pattern Alert System - baoquankhu1.vn
Weekly Recap: Is IGC Pharma Inc likely to announce a buybackExit Point & Fast Entry High Yield Tips - baoquankhu1.vn
Loss Report: Can IGC Pharma Inc deliver alphaJuly 2025 Retail & AI Enhanced Execution Alerts - baoquankhu1.vn
IGC Pharma expands Phase 2 CALMA trial with new clinical site - TipRanks
IGC Pharma Expands Alzheimer's Clinical Trial with New Research Site - GuruFocus
IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship Network Site, in Richmond, Virginia - ACCESS Newswire
Whittier Daily News - FinancialContent
Published on: 2026-01-11 01:25:41 - Улправда
IGC Pharma adjusts fiscal year-end to December 31 - MSN
Can IGC Pharma Inc. stock outperform in 2025 bull marketTrade Risk Summary & Capital Protection Trading Alerts - ulpravda.ru
Why IGC Pharma Inc. stock gets analyst attentionQuarterly Performance Summary & Consistent Return Strategy Ideas - Улправда
Will IGC Pharma Inc. stock deliver long term returnsJuly 2025 Selloffs & Advanced Swing Trade Entry Alerts - Улправда
Can IGC Pharma Inc. stock sustain revenue momentum2025 Investor Takeaways & Low Volatility Stock Suggestions - ulpravda.ru
How IGC Pharma Inc. stock reacts to inflationary pressuresMarket Movers & Fast Momentum Entry Tips - ulpravda.ru
Is IGC Pharma Inc. stock attractive after correctionProfit Target & Low Risk High Reward Trade Ideas - Улправда
Does IGC Pharma Inc. (IGS1) stock trade below intrinsic value2025 Market WrapUp & Weekly Breakout Opportunity Watchlist - ulpravda.ru
Will IGC Pharma Inc. stock outperform Dow Jones indexJuly 2025 EndofMonth & High Win Rate Trade Alerts - Улправда
How IGC Pharma Inc. stock benefits from strong dollarSell Signal & Consistent Profit Trade Alerts - ulpravda.ru
Can IGC Pharma Inc. stock double in next 5 yearsWeekly Volume Report & Weekly Top Performers Watchlists - ulpravda.ru
How dovish Fed policy supports IGC Pharma Inc. (IGS1) stockMarket Risk Analysis & Technical Buy Zone Confirmation - Улправда
Can IGC Pharma Inc. (IGS1) stock sustain institutional flowsCandlestick Pattern Analysis & Smart Trading Plans for Every Investor Type - bollywoodhelpline.com
IGC Pharma (IGC) Aligns Fiscal Year with Calendar Year - GuruFocus
IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability - Finviz
IGC Pharma (NYSE American: IGC) prices direct 779,997-share stock sale - Stock Titan
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75." - Newswire.com
IGC Pharma Announces Registered Direct Equity Offering Financing - TipRanks
IGC Pharma Signs Subscription Agreement With Certain Investors - TradingView — Track All Markets
How IGC Pharma Inc. (IGS1) stock expands through international marketsAutomated Trading Signals & Low Cost Capital Gains - ulpravda.ru
IGC Pharma raises capital to advance IGC-AD1 Phase 2 trial - MSN
IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial - BioSpace
IGC Pharma (NYSE American: IGC) plans $234K registered stock sale - Stock Titan
IGC Pharma (IGC) Secures Funding Through Share Sale - GuruFocus
IGC Pharma, Inc. (IGC) Reports Q4 Loss, Beats Revenue Estimates - MSN
IGC Pharma Adjusts Fiscal Year-End to December 31 - TipRanks
IGC Pharma (IGC) shifts fiscal year-end to December 31 with 9‑month transition - Stock Titan
IGC Pharma, Inc. Approves Change in the Fiscal Year-End from March 31 to December 31 - marketscreener.com
IGC Pharma increases authorized shares to 600 million - MSN
Operating cash flow per share of IGC Pharma, Inc. – SWB:IGS1 - TradingView — Track All Markets
Finanzdaten der IGC Pharma Inc-Aktie (IGC)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.26%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):